 Aileron Therapeutics ALRN, the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer, effective immediately. Mr. Wanstall has served as the Companys Vice President of Finance and Operations and principal accounting officer since 2018. The first is studying ALRN-6924 as a myelopreservation agent to protect cancer patients against chemotherapy-induced toxicities that is currently in a Phase 1b2 clinical study, with data expected to be reported in the second quarter of 2020. 